2. High potassium group SBP: (greater than 100mmol/day) (SEM: 3.92, CI: 2.88) 3. reduced sodium group (50 75mmol/day) DBP: -4.2mmHg – (SEM: 1.88, CI: 4. high potassium, low -0.52) sodium group (greater than 100mmol/day potassium, 50 -75mmol/day sodium) Note only groups 1 and 3 used in this analysis due to confounding effect of potassium (as in Graudal) *Australian National Health and Medical Research Council Dietary Salt Study Management Committee Key features for bias assessment of randomised trials Citation Method of Allocation Blinding Loss to Use of Ceasing Reporting all Funding randomisation concealment follow-up early for outcome results source where benefit required Unclear risk (no Unclear risk (no Participants: <10% (low Yes (low risk) No (low risk) Unclear risk NHMRC description of method description of unclear risk risk) (stated that (low risk) (1986) of sequence method of cholesterol did Providers: generation) concealment of not change high risk allocation) between groups,
2. High potassium group (greater than 100mmol/day) 3. reduced sodium group (50 – 75mmol/day) 4. high potassium, low sodium group (greater than 100mmol/day potassium, 50 -75mmol/day sodium) Note only groups 1 and 3 used in this analysis due to confounding effect of potassium (as in Graudal) SBP: (SEM: 3.92, CI: 2.88) DBP: -4.2mmHg (SEM: 1.88, CI: -0.52) *Australian National Health and Medical Research Council Dietary Salt Study Management Committee Key features for bias assessment of randomised trials Citation Method of randomisation Allocation concealment Blinding Loss to follow-up Use of where required Ceasing early for benefit Reporting all outcome results Funding source (1986) Unclear risk (no description of method of sequence generation) Unclear risk (no description of method of concealment of allocation) Participants: unclear risk Providers: high risk <10% (low risk) Yes (low risk) No (low risk) Unclear risk (stated that cholesterol did not change between groups, NHMRC (low risk)